Oncology
ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C...
At ASCO 2026, BI Global Head of Oncology Itziar Canamasas spoke with pharmaphorum about the company's ASCO data and broader oncology strategy.
News
Moderna jab on trial for cancer-causing syndrome
Patients with Lynch syndrome could have a potential treatment on the horizon, as a Moderna mRNA vaccine starts trials at Oxford University.
News
GSK pursues $10.6bn takeover of cancer biotech Nuvalent
GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.
Patients
ASCO 26: Three cancer survivors share lessons for the field
In honour of National Cancer Survivors' Day, we recount three patient testimonies and calls to action from ASCO Voices at ASCO 2026.
Oncology
ASCO 2026: Chinese firms take a front seat in oncology, with...
Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
